MedTrace Logo

Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer

NCT06312423 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-03-15

No results posted yet for this study

Summary

Phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers.

Conditions

  • Immune System

Interventions

DRUG

Oligonucleotides, Phosphorothioate

Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days

Sponsors & Collaborators

  • Immunalgia Therapeutics S.A.

    collaborator INDUSTRY

  • Ministry of Public Health of the Province of La Rioja

    lead OTHER_GOV

Principal Investigators

  • Eduardo Pirotzky, Doctor · Centro Nuestra Señora del Pilar

  • Alejandro Montaner, Doctor · Immunalgia Therapeutics S.A.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-23
Primary Completion
2024-08-30
Completion
2024-12-30

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06312423 on ClinicalTrials.gov